{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:49:06Z","timestamp":1793638146863,"version":"4.5.1"},"reference-count":139,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:00:00Z","timestamp":1635897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Clinical development of BTK kinase inhibitors for treating autoimmune diseases has lagged behind development of these drugs for treating cancers, due in part from concerns over the lack of selectivity and associated toxicity profiles of first generation drug candidates when used in the long term treatment of immune mediated diseases. Second generation BTK inhibitors have made great strides in limiting off-target activities for distantly related kinases, though they have had variable success at limiting cross-reactivity within the more closely related TEC family of kinases. We investigated the BTK specificity and toxicity profiles, drug properties, disease associated signaling pathways, clinical indications, and trial successes and failures for the 13 BTK inhibitor drug candidates tested in phase 2 or higher clinical trials representing 7 autoimmune and 2 inflammatory immune-mediated diseases. We focused on rheumatoid arthritis (RA), multiple sclerosis (MS), and systemic lupus erythematosus (SLE) where the majority of BTK nonclinical and clinical studies have been reported, with additional information for pemphigus vulgaris (PV), Sjogren\u2019s disease (SJ), chronic spontaneous urticaria (CSU), graft <jats:italic>versus<\/jats:italic> host disease (GVHD), and asthma included where available. While improved BTK selectivity <jats:italic>versus<\/jats:italic> kinases outside the TEC family improved clinical toxicity profiles, less profile distinction was evident within the TEC family. Analysis of genetic associations of RA, MS, and SLE biomarkers with TEC family members revealed that BTK and TEC family members may not be drivers of disease. They are, however, mediators of signaling pathways associated with the pathophysiology of autoimmune diseases. BTK in particular may be associated with B cell and myeloid differentiation as well as autoantibody development implicated in immune mediated diseases. Successes in the clinic for treating RA, MS, PV, ITP, and GVHD, but not for SLE and SJ support the concept that BTK plays an important role in mediating pathogenic processes amenable to therapeutic intervention, depending on the disease. Based on the data collected in this study, we propose that current compound characteristics of BTK inhibitor drug candidates for the treatment of autoimmune diseases have achieved the selectivity, safety, and coverage requirements necessary to deliver therapeutic benefit.<\/jats:p>","DOI":"10.3389\/fimmu.2021.662223","type":"journal-article","created":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T08:35:25Z","timestamp":1635928525000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":142,"title":["Bruton\u2019s Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures"],"prefix":"10.3389","volume":"12","author":[{"given":"Garth E.","family":"Ringheim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Wampole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinsi","family":"Oberoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-Cell-Targeted Therapy With Rituximab in Patients With Rheumatoid Arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-010-1526-y","article-title":"The Efficacy and Safety of Rituximab for the Treatment of Active Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"31","author":"Lee","year":"2011","journal-title":"Rheumatol Int"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2012.64","article-title":"B-Cell-Targeted Therapies in Systemic Lupus Erythematosus","volume":"10","author":"Chan","year":"2013","journal-title":"Cell Mol Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.61.6.667","article-title":"Expression of TNF-Alpha by Human Plasma Cells in Chronic Inflammation","volume":"61","author":"DiGirolamo","year":"1997","journal-title":"J Leukocyte Biol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40259-013-0015-8","article-title":"B-Cell Targeted Therapies in Systemic Lupus Erythematosus: Successes and Challenges","volume":"27","author":"Harvey","year":"2013","journal-title":"BioDrugs"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2014.895810","article-title":"Update on B-Cell Targeted Therapies for Systemic Lupus Erythematosus","volume":"14","author":"Mok","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.074229","article-title":"Assessment of Rituximab\u2019s Immunomodulatory Synovial Effects (ARISE Trial). 1: Clinical and Synovial Biomarker Results","volume":"67","author":"Kavanaugh","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.080960","article-title":"Synovial Tissue Response to Rituximab: Mechanism of Action and Identification of Biomarkers of Response","volume":"67","author":"Thurlings","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.1","article-title":"Long-Lived Autoreactive Plasma Cells Drive Persistent Autoimmune Inflammation","volume":"7","author":"Hiepe","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nri955","article-title":"Regulation of B-Cell Fate by Antigen-Receptor Signals","volume":"2","author":"Niiro","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1385\/IR:23:2-3:147","article-title":"Regulation of B Lymphocyte Development and Activation by Bruton\u2019s Tyrosine Kinase","volume":"23","author":"Khan","year":"2001","journal-title":"Immunol Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-01-0207","article-title":"Pleiotropic Consequences of Bruton Tyrosine Kinase Deficiency in Myeloid Lineages Lead to Poor Inflammatory Responses","volume":"104","author":"Mangla","year":"2004","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00095","article-title":"Toll-Like Receptor Signaling Drives Btk-Mediated Autoimmune Disease","volume":"10","author":"Rip","year":"2019","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0513307","article-title":"Bruton\u2019s Tyrosine Kinase\u2013an Integral Protein of B Cell Development That Also has an Essential Role in the Innate Immune System","volume":"95","author":"Lopez-Herrera","year":"2014","journal-title":"J Leukoc Biol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.immuni.2006.11.012","article-title":"Bruton\u2019s Tyrosine Kinase and Phospholipase Cgamma2 Mediate Chemokine-Controlled B Cell Migration and Homing","volume":"26","author":"de Gorter","year":"2007","journal-title":"Immunity"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.071043","article-title":"Btk-Dependent Rac Activation and Actin Rearrangement Following FcepsilonRI Aggregation Promotes Enhanced Chemotactic Responses of Mast Cells","volume":"123","author":"Kuehn","year":"2010","journal-title":"J Cell Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-9822(98)70471-3","article-title":"A Role for Bruton\u2019s Tyrosine Kinase (Btk) in Platelet Activation by Collagen","volume":"8","author":"Quek","year":"1998","journal-title":"Curr Biol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.cell.2007.12.037","article-title":"Tyrosine Kinases Btk and Tec Regulate Osteoclast Differentiation by Linking RANK and ITAM Signals","volume":"132","author":"Shinohara","year":"2008","journal-title":"Cell"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4172\/2155-9899.1000205","article-title":"The Pathogenesis of Lupus Nephritis","volume":"5","author":"Sterner","year":"2014","journal-title":"J Clin Cell Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2013010026","article-title":"The Pathogenesis of Lupus Nephritis","volume":"24","author":"Lech","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton Tyrosine Kinase Inhibitor PCI-32765 Blocks B-Cell Activation and Is Efficacious in Models of Autoimmune Disease and B-Cell Malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1038\/s41467-020-16128-5","article-title":"Btk SH2-Kinase Interface Is Critical for Allosteric Kinase Activation and Its Targeting Inhibits B-Cell Neoplasms","volume":"11","author":"Duarte","year":"2020","journal-title":"Nat Commun"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/bies.1062","article-title":"The Tec Family of Cytoplasmic Tyrosine Kinases: Mammalian Btk, Bmx, Itk, Tec, Txk and Homologs in Other Species","volume":"23","author":"Smith","year":"2001","journal-title":"Bioessays"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/10409238.2018.1495173","article-title":"The Src Module: An Ancient Scaffold in the Evolution of Cytoplasmic Tyrosine Kinases","volume":"53","author":"Shah","year":"2018","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrm1280","article-title":"Regulation of the C-Abl and Bcr-Abl Tyrosine Kinases","volume":"5","author":"Hantschel","year":"2004","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2020.88475","article-title":"Second-Generation BTK Inhibitors Hit the Treatment Bullseye With Fewer Off-Target Effects","volume":"26","author":"Shaw","year":"2020","journal-title":"Am J Manag Care"},{"key":"B27","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-60761-175-2_10","article-title":"Functional Analysis of OMICs Data and Small Molecule Compounds in an Integrated \u201cKnowledge-Based\u201d Platform","volume-title":"Protein Networks and Pathway Analysis. Methods in Molecular Biology (Methods and Protocols).","author":"Nikolsky","year":"2009"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.2949","article-title":"Op0233 Efficacy, Safety, and Pharmacodynamic Effects of the Bruton\u2019s Tyrosine Kinase Inhibitor, Fenebrutinib (Gdc-0853), in Moderate to Severe Systemic Lupus Erythematosus in a Phase 2 Controlled Study","volume":"79","author":"Isenberg","year":"2020","journal-title":"Ann Rheumatic Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/art.41538","article-title":"Efficacy and Safety of Evobrutinib (M2951) in Adult Patients With Systemic Lupus Erythematosus Who Received Standard of Care Therapy: A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose Ranging Study","volume":"72","author":"Wallace","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.06.023","article-title":"Ibrutinib for Chronic Graft-Versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b\/2 Study","volume":"25","author":"Waller","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6b01088","article-title":"Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-Fluoro-1-Methyl-2,4-Dioxo-1,2-Dihydroquinazolin-3(4H)-Yl)-2-Methylphenyl)-2-(S)-(2-Hydroxypropan-2-Yl)-2,3,4,9-Tetrahydro-1H-Carbazole-8- Carboxamide (BMS-986142): A Reversible Inhibitor of Bruton\u2019s Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers","volume":"59","author":"Watterson","year":"2016","journal-title":"J Med Chem"},{"key":"B32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181782","article-title":"Bruton's Tyrosine Kinase Inhibitor BMS-986142 in Experimental Models of Rheumatoid Arthritis Enhances Efficacy of Agents Representing Clinical Standard-of-Care","volume-title":"PLoS One","author":"Gillooly","year":"2017"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00167","article-title":"Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton\u2019s Tyrosine Kinase (BTK)","volume":"62","author":"Watterson","year":"2019","journal-title":"J Med Chem"},{"key":"B34","volume-title":"Indole Carboxamides Compounds Useful as Kinase Inhibitors.","author":"Ahmad","year":"2014"},{"key":"B35","volume-title":"Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis Rate. WIPO Patent WO2017025814","author":"Lannutti","year":"2015"},{"key":"B36","unstructured":"Considerations in the Generation of Covalent BTK Inhibitors\n            VasudevanA\n            WilsonN\n            FrankK\n            XuX\n            FriedmanM\n            HoemannM\n          Cambridge, United Kingdom19th RSC\/SCI Med Chem Symposium [Conference Presentation]2017"},{"key":"B37","article-title":"Efficacy of ABBV-105, A Selective and Irreversible Inhibitor of Bruton\u2019s Tyrosine Kinase (BTK), in Multiple Models of Inflammation","volume-title":"Arthritis Rheumatol","author":"Goess","year":"2015"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800583","article-title":"Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models","volume":"202","author":"Haselmayer","year":"2019","journal-title":"J Immunol"},{"key":"B39","article-title":"Discovery of M2951: A Selective, Covalent Inhibitor of BTK for the Treatment of Autoimmune Diseases","volume-title":"254th Am Chem Soc Natl Meet","author":"Goutopoulos","year":"2017"},{"key":"B40","volume-title":"Inventormethods for Treating MS Using Pyrimidine and Pyridine Compounds With BTK Inhibitory Activity.","author":"Dellovade","year":"2015"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-eular.434251","article-title":"THU0275 Pharmacodynamic Modeling of BTK Occupancy Versus Efficacy in RA and SLE Models Using the Novel Specific BTK Inhibitor M2951","volume":"75","author":"Haselmayer","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B42","unstructured":"Discovery of GDC-0853: A Potent Selective BTK Inhibitor for the Treatment of Lupus and Rheumatoid Arthritis\n            YoungWB\n          San Francisco, USA253rd Am Chem Soc Natl Meet2017"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b01712","article-title":"Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton\u2019s Tyrosine Kinase Inhibitor in Early Clinical Development","volume":"61","author":"Crawford","year":"2018","journal-title":"J Med Chem"},{"key":"B44","volume-title":"Inhibitors of Bruton\u2019s Tyrosine Kinase.","author":"Honigberg","year":"2006"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.9b00395","article-title":"Discovery and Evaluation of Pyrazolo[3,4-D]Pyridazinone as a Potent and Orally Active Irreversible BTK Inhibitor","volume":"11","author":"Zhang","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"B46","unstructured":"TG-1701 a Novel, Orally Available, and Covalently-Bound Btk Inhibitor\n            NormantE\n            GorelikL\n            ShmeisR\n            LeH\n            NischR\n            MiskinHP\n          Stockholm, Sweden23rd Congr Eur Hematol Assoc (EHA)2018"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.02.077","article-title":"Design, Synthesis and Evaluation of Novel 7H-Pyrrolo[2,3-D]Pyrimidin-4-Amine Derivatives as Potent, Selective and Reversible Bruton\u2019s Tyrosine Kinase (BTK) Inhibitors for the Treatment of Rheumatoid Arthritis","volume":"169","author":"Zhang","year":"2019","journal-title":"Eur J Med Chem"},{"key":"B48","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s13075-017-1402-1","article-title":"HM71224, A Selective Bruton's Tyrosine Kinase Inhibitor, Attenuates the Development of Murine Lupus","volume":"19","author":"Kim","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"B49","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13075-016-0988-z","article-title":"HM71224, a Novel Bruton\u2019s Tyrosine Kinase Inhibitor, Suppresses B Cell and Monocyte Activation and Ameliorates Arthritis in a Mouse Model: A Potential Drug for Rheumatoid Arthritis","volume":"18","author":"Park","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-eular.3059","article-title":"HM71224, A Novel BTK Inhibitor Demonstrates Potent Activities in Rodent Models of Arthritis","volume":"73","author":"Jang","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B51","article-title":"LOU064: A Highly Selective and Potent Covalent Oral BTK Inhibitor with Promising Pharmacodynamic Efficacy on B Cells for Sjoegren\u2019s Syndrome","volume":"71","author":"Cenni","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b01916","article-title":"Discovery of LOU064 (Remibrutinib), A Potent and Highly Selective Covalent Inhibitor of Bruton\u2019s Tyrosine Kinase","volume":"63","author":"Angst","year":"2020","journal-title":"J Med Chem"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-eular.3641","article-title":"Preclinical Characterization of PRN1008, A Novel Reversible Covalent Inhibitor of BTK that Shows Efficacy in a Rat Model of Collagen-Induced Arthritis","volume":"74","author":"Hill","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B54","first-page":"1052","article-title":"PRN1008, A Reversible Covalent BTK Inhibitor in Clinical Development for Immune Thrombocytopenic Purpura","volume":"130","author":"Langrish","year":"2017","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.113.203489","article-title":"Inhibition of Btk With CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans","volume":"346","author":"Evans","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"B56","first-page":"263","article-title":"Inhibition of Btk with AVL-292 Translates to Protective Activity In Animal Models of Rheumatoid Arthritis","volume-title":"16th Bienn Int Conf Inflamm Res Assoc","author":"Karp","year":"2010"},{"key":"B57","volume-title":"Methods of Treating a Bruton\u2019s Tyrosine Kinase Disease or Disorder. WIPO Patent WO2014039452","author":"Westlin","year":"2012"},{"key":"B58","unstructured":"ONO-4059 - A Highly Potent and Dual Oral Inhibitor of Bruton\u2019s Tyrosine Kinase (Btk) and Tec Kinase: Improves Anti-Nuclear Antibodies-Mediated SLE in Mice\n            ArizaY\n            YoshizawaT\n            UedaY\n            MurataM\n            KawabataK\n          Boston, USA78th Annu Sci Meet Am Coll Rheumatol2012"},{"key":"B59","article-title":"Targeting the BTK-JAK Axis in Preclinical Models of Rat Collagen-Induced Arthritis With GS-4059 in Combination With a JAK Inhibitor","volume":"68","author":"Di Paolo","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B60","unstructured":"Development of a Bruton\u2019s Tyrosine Kinase (BTK) Inhibitor, ONO-4059: Efficacy in a Collagen Induced Arthritis (CIA) Model Indicates Potential Treatment for Rheumatoid Arthritis (RA)\n            YoshizawaT\n            ArizaY\n            UedaY\n            HottaS\n            NaritaM\n            KawabataK\n          Washington, D.C., USA76th Annu Sci Meet Am Coll Rheumatol2012"},{"key":"B61","first-page":"Poster 989","volume-title":"PRN2246, a Potent and Selective Blood Brain Barrier Penetrating BTK Inhibitor, Exhibits Efficacy in Central Nervous System Immunity","author":"Francesco","year":"2017"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3892\/or.2019.7364","article-title":"Ibrutinib in CLL\/SLL: From Bench to Bedside (Review)","volume":"42","author":"Zi","year":"2019","journal-title":"Oncol Rep"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-793786","article-title":"Ibrutinib for Chronic Graft-Versus-Host Disease After Failure of Prior Therapy","volume":"130","author":"Miklos","year":"2017","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2020.129531","article-title":"Biochemical Characterization of Tirabrutinib and Other Irreversible Inhibitors of Bruton\u2019s Tyrosine Kinase Reveals Differences in On - and Off - Target Inhibition","volume":"1864","author":"Liclican","year":"2020","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N Engl J Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3505","article-title":"Pharmacodynamic Analysis of BTK Inhibition in Patients With Chronic Lymphocytic Leukemia Treated With Acalabrutinib","volume":"26","author":"Alsadhan","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-019-00182-7","article-title":"Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients With Rheumatoid Arthritis: Results From a Mechanistic Study","volume":"7","author":"Schafer","year":"2020","journal-title":"Rheumatol Ther"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1126\/science.8332901","article-title":"Mutation of Unique Region of Bruton\u2019s Tyrosine Kinase in Immunodeficient XID Mice","volume":"261","author":"Rawlings","year":"1993","journal-title":"Science"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/1074-7613(95)90114-0","article-title":"Defective B Cell Development and Function in Btk-Deficient Mice","volume":"3","author":"Khan","year":"1995","journal-title":"Immunity"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1126\/science.8332900","article-title":"Colocalization of X-Linked Agammaglobulinemia and X-Linked Immunodeficiency Genes","volume":"261","author":"Thomas","year":"1993","journal-title":"Science"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90667-F","article-title":"Deficient Expression of a B Cell Cytoplasmic Tyrosine Kinase in Human X-Linked Agammaglobulinemia","volume":"72","author":"Tsukada","year":"1993","journal-title":"Cell"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/361226a0","article-title":"The Gene Involved in X-Linked Agammaglobulinaemia Is a Member of the Src Family of Protein-Tyrosine Kinases","volume":"361","author":"Vetrie","year":"1993","journal-title":"Nature"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.4.1850","article-title":"Reduced Dosage of Bruton\u2019s Tyrosine Kinase Uncouples B Cell Hyperresponsiveness From Autoimmunity in Lyn-\/- Mice","volume":"171","author":"Whyburn","year":"2003","journal-title":"J Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1002\/art.41275","article-title":"Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial (ANDES Study)","volume":"72","author":"Cohen","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"R90","DOI":"10.1186\/ar4555","article-title":"Synovial Phenotypes in Rheumatoid Arthritis Correlate With Response to Biologic Therapeutics","volume":"16","author":"Dennis","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1002\/art.39657","article-title":"Bruton\u2019s Tyrosine Kinase Deficiency Inhibits Autoimmune Arthritis in Mice But Fails to Block Immune Complex-Mediated Inflammatory Arthritis","volume":"68","author":"Nyhoff","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jaut.2013.12.002","article-title":"The Effect of B-Cell Depletion Therapy on Serological Evidence of B-Cell and Plasmablast Activation in Patients With Rheumatoid Arthritis Over Multiple Cycles of Rituximab Treatment","volume":"50","author":"Cambridge","year":"2014","journal-title":"J Autoimmun"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12481","article-title":"Usefulness of Monitoring of B Cell Depletion in Rituximab-Treated Rheumatoid Arthritis Patients in Order to Predict Clinical Relapse: A Prospective Observational Study","volume":"180","author":"Trouvin","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41590-018-0135-x","article-title":"Reassessing B Cell Contributions in Multiple Sclerosis","volume":"19","author":"Li","year":"2018","journal-title":"Nat Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2020.1807934","article-title":"Inhibition of Bruton s Tyrosine Kinase as a Novel Therapeutic Approach in Multiple Sclerosis","volume":"29","author":"Torke","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901981","article-title":"Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis","volume":"380","author":"Montalban","year":"2019","journal-title":"N Engl J Med"},{"key":"B82","unstructured":"Sanofi Brain-Penetrant BTK Inhibitor Significantly Reduced Disease Activity in Phase 2 Trial in Relapsing Multiple Sclerosis 2020."},{"key":"B83","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00281-015-0541-1","article-title":"Immune Response in Pemphigus and Beyond: Progresses and Emerging Concepts","volume":"38","author":"Di Zenzo","year":"2016","journal-title":"Semin Immunopathol"},{"key":"B84","unstructured":"MurrellDF\n            StavroupoulosP\n            PatsatsiA\n            BaumS\n            RoussakiA\n            KernJS\n          Clinical Endpoint Analysis of the Believe-PV Phase 2 Study of PRN1008 in Pemphigus [PDF].2018"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/S0037-1963(00)90102-1","article-title":"Autoantibodies and Autoantigens in Chronic Immune Thrombocytopenic Purpura","volume":"37","author":"McMillan","year":"2000","journal-title":"Semin Hematol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-122336","article-title":"Phase I\/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients With Relapsed\/Refractory Primary or Secondary Immune Thrombocytopenia","volume":"134","author":"Cooper","year":"2019","journal-title":"Blood"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00627","article-title":"Autoimmune Theories of Chronic Spontaneous Urticaria","volume":"10","author":"Bracken","year":"2019","journal-title":"Front Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13005","article-title":"Remibrutinib (LOU064): A Selective Potent Oral BTK Inhibitor With Promising Clinical Safety and Pharmacodynamics in a Randomized Phase I Trial","volume":"14","author":"Kaul","year":"2021","journal-title":"Clin Transl Sci"},{"key":"B89","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.3390\/jcm9072299","article-title":"Current State of Knowledge on Primary Sjogren\u2019s Syndrome, an Autoimmune Exocrinopathy","volume":"9","author":"Parisis","year":"2020","journal-title":"J Clin Med"},{"key":"B90","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.3390\/ijms20236021","article-title":"Multiple Functions of B Cells in the Pathogenesis of Systemic Lupus Erythematosus","volume":"20","author":"Ma","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1002\/art.40059","article-title":"Enhanced Bruton's Tyrosine Kinase Activity in Peripheral Blood B Lymphocytes From Patients With Autoimmune Disease","volume":"69","author":"Corneth","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2012.09.013","article-title":"Novel Autoantibodies in Sjogren\u2019s Syndrome","volume":"145","author":"Shen","year":"2012","journal-title":"Clin Immunol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1002\/art.39448","article-title":"Preliminary Results of a Double-Blind Randomised Trial of Rituximab Anti-B-Cell Therapy in Patients With Primary Sjogrens Syndrome","volume":"67","author":"Bowman","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200001)30:1<145::AID-IMMU145>3.0.CO;2-0","article-title":"Redistribution of Bruton\u2019s Tyrosine Kinase by Activation of Phosphatidylinositol 3-Kinase and Rho-Family GTPases","volume":"30","author":"Nore","year":"2000","journal-title":"Eur J Immunol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1471-2172-2-4","article-title":"A Conditional Form of Bruton\u2019s Tyrosine Kinase Is Sufficient to Activate Multiple Downstream Signaling Pathways via PLC Gamma 2 in B Cells","volume":"2","author":"Tomlinson","year":"2001","journal-title":"BMC Immunol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.1088","article-title":"Bruton\u2019s Tyrosine Kinase Associates With the Actin-Based Cytoskeleton in Activated Platelets","volume":"81","author":"Mukhopadhyay","year":"2001","journal-title":"J Cell Biochem"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.182.1.329","article-title":"Btk Regulates B Cell Receptor-Mediated Antigen Processing and Presentation by Controlling Actin Cytoskeleton Dynamics in B Cells","volume":"182","author":"Sharma","year":"2009","journal-title":"J Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1100157","article-title":"A Balance of Bruton\u2019s Tyrosine Kinase and SHIP Activation Regulates B Cell Receptor Cluster Formation by Controlling Actin Remodeling","volume":"187","author":"Liu","year":"2011","journal-title":"J Immunol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41573-020-0082-8","article-title":"Kinase Inhibition in Autoimmunity and Inflammation","volume":"20","author":"Zarrin","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2005.01.018","article-title":"Autoimmunity and Inflammation Due to a Gain-of-Function Mutation in Phospholipase C Gamma 2 That Specifically Increases External Ca2+ Entry","volume":"22","author":"Yu","year":"2005","journal-title":"Immunity"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1186\/ar1806","article-title":"Pro-Inflammatory Properties of Stromal Cell-Derived Factor-1 (CXCL12) in Collagen-Induced Arthritis","volume":"7","author":"De Klerck","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3083.2001.00970.x","article-title":"Chemokines and Cell Trafficking in Sjogren\u2019s Syndrome","volume":"54","author":"Amft","year":"2001","journal-title":"Scand J Immunol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.7.5130","article-title":"CXCL13, CCL21, and CXCL12 Expression in Salivary Glands of Patients With Sjogren\u2019s Syndrome and MALT Lymphoma: Association With Reactive and Malignant Areas of Lymphoid Organization","volume":"180","author":"Barone","year":"2008","journal-title":"J Immunol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker019","article-title":"Chemokine Saliva Levels in Patients With Primary Sjogren\u2019s Syndrome, Associated Sjogren\u2019s Syndrome, Pre-Clinical Sjogren\u2019s Syndrome and Systemic Autoimmune Diseases","volume":"50","author":"Hernandez-Molina","year":"2011","journal-title":"Rheumatol (Oxford)"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200201)46:1<130::AID-ART10020>3.0.CO;2-D","article-title":"Stimulation of Matrix Metalloprotease 3 Release From Human Chondrocytes by the Interaction of Stromal Cell-Derived Factor 1 and CXC Chemokine Receptor 4","volume":"46","author":"Kanbe","year":"2002","journal-title":"Arthritis Rheum"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.10445","article-title":"CXCL12 Chemokine Up-Regulates Bone Resorption and MMP-9 Release by Human Osteoclasts: CXCL12 Levels Are Increased in Synovial and Bone Tissue of Rheumatoid Arthritis Patients","volume":"199","author":"Grassi","year":"2004","journal-title":"J Cell Physiol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1002\/art.20743","article-title":"Association Between Stromal Cell-Derived Factor 1 Chemokine Gene Variant and Radiographic Progression of Rheumatoid Arthritis","volume":"52","author":"Joven","year":"2005","journal-title":"Arthritis Rheum"},{"key":"B108","article-title":"Plasma Level of CXC-Chemokine CXCL12 Is Increased in Rheumatoid Arthritis and Is Independent of Disease Activity and Methotrexate Treatment","volume":"33","author":"Hansen","year":"2006","journal-title":"J Rheumatol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gene.6364299","article-title":"Multifactor Dimensionality Reduction Reveals Gene-Gene Interactions Associated With Multiple Sclerosis Susceptibility in African Americans","volume":"7","author":"Brassat","year":"2006","journal-title":"Genes Immun"},{"key":"B110","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2353\/ajpath.2008.070918","article-title":"Pathological Expression of CXCL12 at the Blood-Brain Barrier Correlates With Severity of Multiple Sclerosis","volume":"172","author":"McCandless","year":"2008","journal-title":"Am J Pathol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.2174\/1381612043384538","article-title":"Modulation of the Fcepsilon Receptor I Signaling by Tyrosine Kinase Inhibitors: Search for Therapeutic Targets of Inflammatory and Allergy Diseases","volume":"10","author":"Luskova","year":"2004","journal-title":"Curr Pharm Des"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.11.7706","article-title":"The Phosphoinositide 3-Kinase-Dependent Activation of Btk Is Required for Optimal Eicosanoid Production and Generation of Reactive Oxygen Species in Antigen-Stimulated Mast Cells","volume":"181","author":"Kuehn","year":"2008","journal-title":"J Immunol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1208724","article-title":"Early Signal Protein Expression Profiles in Basophils: A Population Study","volume":"86","author":"Ishmael","year":"2009","journal-title":"J Leukoc Biol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2010.12.018","article-title":"Inhibition of IgE-Mediated Secretion From Human Basophils With a Highly Selective Bruton\u2019s Tyrosine Kinase, Btk, Inhibitor","volume":"11","author":"MacGlashan","year":"2011","journal-title":"Int Immunopharmacol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3109\/08830185.2012.663838","article-title":"BMX and Its Role in Inflammation, Cardiovascular Disease, and Cancer","volume":"31","author":"Cenni","year":"2012","journal-title":"Int Rev Immunol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1002813","article-title":"The Tyrosine Kinase BMX Is an Essential Mediator of Inflammatory Arthritis in a Kinase-Independent Manner","volume":"186","author":"Gottar-Guillier","year":"2011","journal-title":"J Immunol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.4103\/2321-3868.135483","article-title":"Current Understanding of Tyrosine Kinase BMX in Inflammation and Its Inhibitors","volume":"2","author":"Qiu","year":"2014","journal-title":"Burns Trauma"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.96.6.1729","article-title":"Bmx Tyrosine Kinase Is Specifically Expressed in the Endocardium and the Endothelium of Large Arteries","volume":"96","author":"Ekman","year":"1997","journal-title":"Circulation"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1517810112","article-title":"Endothelial Bmx Tyrosine Kinase Activity Is Essential for Myocardial Hypertrophy and Remodeling","volume":"112","author":"Holopainen","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.14663","article-title":"Nuclear Localization of the Tyrosine Kinase BMX Mediates VEGFR2 Expression","volume":"24","author":"Liu","year":"2020","journal-title":"J Cell Mol Med"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.21.14.4647-4655.2001","article-title":"Bmx Tyrosine Kinase has a Redundant Function Downstream of Angiopoietin and Vascular Endothelial Growth Factor Receptors in Arterial Endothelium","volume":"21","author":"Rajantie","year":"2001","journal-title":"Mol Cell Biol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-102343","article-title":"Bmx Tyrosine Kinase Regulates TLR4-Induced IL-6 Production in Human Macrophages Independently of P38 MAPK and NFkapp}B Activity","volume":"111","author":"Palmer","year":"2008","journal-title":"Blood"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton\u2019s Tyrosine Kinase","volume":"62","author":"Guo","year":"2019","journal-title":"J Med Chem"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance Mechanisms for the Bruton\u2019s Tyrosine Kinase Inhibitor Ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTK(C481S)-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J Clin Oncol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000854","article-title":"Prevalence of BTK and PLCG2 Mutations in a Real-Life CLL Cohort Still on Ibrutinib After 3 Years: A FILO Group Study","volume":"134","author":"Quinquenel","year":"2019","journal-title":"Blood"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001319","article-title":"Novel Mouse Model Resistant to Irreversible BTK Inhibitors: A Tool Identifying New Therapeutic Targets and Side Effects","volume":"4","author":"Estupinan","year":"2020","journal-title":"Blood Adv"},{"key":"B128","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3390\/life10120344","article-title":"Cardiotoxicity of Novel Targeted Hematological Therapies","volume":"10","author":"Giudice","year":"2020","journal-title":"Life (Basel)"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-716977","article-title":"Outcomes of CLL Patients Treated With Sequential Kinase Inhibitor Therapy: A Real World Experience","volume":"128","author":"Mato","year":"2016","journal-title":"Blood"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S219570","article-title":"Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data","volume":"12","author":"Isaac","year":"2020","journal-title":"Cancer Manag Res"},{"key":"B131","unstructured":"First Interim Analysis of ALPINE Study: Results of a Phase 3 Randomized Study of Zanubrutinib vs Ibrutinib in Patients With Relapsed\/Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic LymphomaLB1900\n            HillmenP\n            EichhorstB\n            BrownJR\n            LamannaN\n            O'BrienS\n            ConstantineS\n          Eur Hematol Association: Presidential Symposium.2011"},{"key":"B132","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.critrevonc.2019.02.001","article-title":"Management of Adverse Effects\/Toxicity of Ibrutinib","volume":"136","author":"Paydas","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.242909","article-title":"Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor With a Differentiated Selectivity and In Vivo Pot Ip789ency Profile","volume":"363","author":"Barf","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"B134","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13045-016-0250-9","article-title":"Acalabrutinib (ACP-196): A Selective Second-Generation BTK Inhibitor","volume":"9","author":"Wu","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-583294","article-title":"Ibrutinib Treatment Affects Collagen and Von Willebrand Factor-Dependent Platelet Functions","volume":"124","author":"Levade","year":"2014","journal-title":"Blood"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-205328","article-title":"The New Tyrosine-Kinase Inhibitor and Anticancer Drug Dasatinib Reversibly Affects Platelet Activation In Vitro and In Vivo","volume":"114","author":"Gratacap","year":"2009","journal-title":"Blood"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13148","article-title":"The Effect of Bruton\u2019s Tyrosine Kinase (BTK) Inhibitors on Collagen-Induced Platelet Aggregation, BTK, and Tyrosine Kinase Expressed in Hepatocellular Carcinoma (TEC)","volume":"101","author":"Chen","year":"2018","journal-title":"Eur J Haematol"},{"key":"B138","volume-title":"A Phase II Study of M2951 in Systemic Lupus Erythematosus (SLE)","year":"2016"},{"key":"B139","doi-asserted-by":"publisher","first-page":"764","DOI":"10.3390\/jpm11080764","article-title":"Non-Covalent BTK Inhibitors-The New BTKids on the Block for B-Cell Malignancies","volume":"11","author":"Lewis","year":"2021","journal-title":"J Pers Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.662223\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T08:35:57Z","timestamp":1635928557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.662223\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,3]]},"references-count":139,"alternative-id":["10.3389\/fimmu.2021.662223"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.662223","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,3]]},"article-number":"662223"}}